InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Twenty cases that will change the way you work


Managing IP's cases of the year for 2012 includes the annual top 10, plus 10 smaller rulings you might have missed. By Emma Barraclough, Simon Crompton, Peter Leung, Paul Madill, Eileen McDermott, James Nurton and Alli Pyrah

This has not been a year for blockbuster cases. Even though the volume of litigation remains high, neither Europe nor Asia has thrown up many surprising results. And though the United States has given us Louboutin's red-soled shoes and the first jury trial in Apple v Samsung, both cases covered issues that had been raised the year before.

Rather, 2012 was characterised by a series of cases with important but...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

Just been interviewing Fred Reinhart, president of @AUTM_Network V interesting chat about open innovation - will be on the site next week

Jun 30 2015 05:05 ·  reply ·  retweet ·  favourite
ManagingIP profile

New EU General Court rules effective tomorrow http://t.co/asyjufhrs9 More info here ($/trial) http://t.co/0P9ESxFke4 Imp't for OHIM appeals

Jun 30 2015 03:51 ·  reply ·  retweet ·  favourite
ManagingIP profile

Why biotechs may prefer trade secrets to patents - @mdloney reports from #BIO2015 http://t.co/n7MyHccpab ($/trial) http://t.co/8cTcxSHj9M

Jun 30 2015 02:04 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements